Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586070 | 0.89 | ACHE (0.78) | ACHEBACE1ALOX5PTGS2STAT3 | |
| SCHEMBL9651750 | 0.84 | ACHE (0.55) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL10600348 | 0.77 | ACHE (0.52) | ACHEBACE1MAOAMAOBALDH1A1 | |
| SCHEMBL14680383 | 0.76 | ACHE (0.80) | ACHEBACE1ALOX5PTGS2STAT3 | |
| SCHEMBL11018415 | 0.75 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2STAT3 | |
| SCHEMBL3264783 | 0.75 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2STAT3 | |
| SCHEMBL10701374 | 0.75 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2STAT3 | |
| SCHEMBL10704172 | 0.75 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2STAT3 | |
| SCHEMBL10702354 | 0.75 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2STAT3 | |
| SCHEMBL20875697 | 0.75 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130216-A1 | COMPOUNDS FOR PROMOTING LIPOSOMAL AND CELLULAR ADHESION AND COMPOSITIONS AND METHODS OF USE THEREOF | ORGANOLINX CORP. (CA) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130216-A1 | COMPOUNDS FOR PROMOTING LIPOSOMAL AND CELLULAR ADHESION AND COMPOSITIONS AND METHODS OF USE THEREOF | LPAR2, SGMS2, PHOSPHO1 | ACHE 2068/4885BACE1 1740/4885ALOX5 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.